Cardiac monitoring should ideally be initiated prior to the start of cancer treatment to establish a baseline. This helps in identifying pre-existing cardiovascular conditions and assessing risk. Ongoing monitoring is recommended during and after treatment, especially for therapies known to have cardiotoxic effects. The frequency of monitoring depends on the type of therapy, dosage, and patient risk factors.
